Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-08-27

Study Completion Date

2025-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has been planned as part of the Orthofix Srl post-market active surveillance plan for the collection of data on both the clinical performance and the safety profile of the JTIN.

The rationale of the proposed study is to update and support the pre-market clinical evaluation of the JTIN with Real World Evidence clinical data in a real-life surgical setting, in order to confirm the benefit/risk ratio of this medical device and to keep the CE mark under Medical Device Regulation (MDR) requirements. One selected site, experienced in the treatment of pediatric patients with OI, where the usage of JTIN is already part of the normal clinical practice, will participate in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Study on Clinical Performance and Safety Profile of MJ-Flex Elastic Nail

NCT06412913

Fractures, Bone

TERMINATED

Retrospective Study on Clinical Performance and Safety Profile of Agile Nail

NCT06412939

Fractures, Bone Impending Fracture Deformity; Bone

TERMINATED

Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture

NCT00512434

Tibial Fractures Fractures, Open

COMPLETED NA

Management of Closed Diaphyseal Displaced Leg Fractures in Children and Adolescents

NCT06503718

Tibial Fractures

RECRUITING

Pediatric Orthopaedic Implant Safety & Efficacy

NCT05361980

Fracture Lengthening; Leg Orthopedic Disorder +8 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One selected site, experienced in the treatment of pediatric patients with OI, where the usage of JTIN is already part of the normal clinical practice, will participate in this study. Investigator will screen patients treated (or planned to be treated) with JTIN to verify inclusion and exclusion criteria, to achieve the enrollment of 25 cases. With lost to follow-up percentage estimated at 20%, this will lead to a total of 20 evaluable cases, i.e. 20 implanted JTIN (some patients may contribute for more than one implant). Patients are prospectively and retrospectively enrolled in the study: they may have undergone JTIN implantation from the 1st of January 2022.

Enrolled patients, since this study is non-interventional and observational, will follow the standard medical practice of the site: no requirements regarding the treatment of patients will be imposed on the site or Principal Investigator and the Sponsor will not in any manner influence the treatment decisions. Data of enrolled subjects will be collected for this study up to 1 year from surgery.

The hospital standard care usually, but not exclusively, includes: surgery, discharge and plaster removal visits, and then 3 other follow up visits up to 1 year from surgery (see "Visits and Assessments Schedule"). Visits frequency is estimated as average of the site normal clinical practice, actual visit timing for each patient will be performed according to investigators and hospital staff evaluation.

The patient data will be systematically collected by the investigator in eCRF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteogenesis Imperfecta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JTIN treated patients

Pediatric patients, older than 18 months, suffering from osteogenesis imperfecta treated with JTIN telescopic nail

JTIN implantation surgery

Intervention Type DEVICE

The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JTIN implantation surgery

The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* is in pediatric age (\> 18 month and \< 18 years) at the time of surgery;
* is skeletally immature;
* has a diagnosis for OI;
* has a regular indication for surgical intervention with JTIN to treat femoral and/or tibial fractures, osteotomies, malunions and non-unions;
* patient and/or legal representative is duly informed and doesn't oppose to participation.

Exclusion Criteria

* has a medical condition that is a contraindication according to the manufacturer's instruction for use;
* has any conditions that in the Investigator's opinion may interfere with the study execution or due to which the patient should not participate for safety reasons;
* requires the application of, or has already in-situ the application of concomitant devices that cannot be safely removed (except for permitted concomitant devices paragraph);
* is participating in other clinical trials or has taken part in any clinical study in the last 3 months with exception of analytical trials on genetics study related to OI (i.e. studies that do not include an investigational treatment for the patient such as new drugs or other medical devices);
* is likely to be lost to follow up, according to investigator's opinion.

Minimum Eligible Age

18 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No